DPP-4 Therapy Center

Precision diabetes treatment aims to answer a question clinicians and patients face every day: which diabetes drug is most likely to work best for this particular person? A new analysis from the TriMaster crossover trial offers an important clue. Researchers compared several precision-medicine strategies for predicting responses to sitagliptin, canagliflozin, …

In recent years, the role of incretin therapy in cardiovascular disease management has gained attention as new outcomes data reshape how clinicians approach high-risk patients. But should treatment choices really change based on these findings? As evidence evolves, many providers are reconsidering which therapies deliver both glycemic control and cardiovascular …

Diabetes is a chronic disease that affects millions of people worldwide. As such, many treatments have been developed over the years in order to help people manage their condition. One such class of medications is DPP-4 inhibitors, which have recently been gaining attention for their potential in diabetes care. In …

Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by high blood sugar levels. It is most commonly diagnosed in adults, but it is becoming increasingly common in children and adolescents.  Youth-onset T2D is a more severe form of the disease than adult-onset T2D. It is often associated with …

Glucagon-like peptide-1 (GLP-1) receptor agonist can reduce mortality and improve cardiovascular outcomes among patients with type 2 diabetes and end-stage kidney disease, compared to dipeptidyl peptidase -4 inhibitor use.

New retrospective study results compare the two most primarily prescribed antidiabetic medication classes in addition to metformin to determine the impact on the incidence of CV events in patients with T2DM.

DPP4 inhibitors may restore the normal functioning of vascular endothelium in patients who require insulin treatment. 

According to current research, linagliptin had a significantly lower risk of hypoglycemia and adverse events in geriatric patients with type 2 diabetes. 

DPP-4i may lower the amyloid burden in Alzheimer’s patients and improve cognitive impairment. 

The GRADE Study is the most comprehensive study comparing multiple diabetic medications to assess efficacy in type 2 diabetes. So which drug therapy reigned supreme?